FTSE 100 Live 05 February: Index seen lower, GSK lifts long-term sales outlook GSK today increased its 2031 sales outlook to more than £40 billion, up from £38 billion amid stronger progress in its late-stage drugs pipeline.
Chief executive Emma Walmsley said: "GSK delivered another year of excellent performance in 2024, with strong sales and core profit growth driven by accelerating momentum of our specialty medicines portfolio.
“This, together with outstanding phase III pipeline progress, means we expect another year of profitable growth in 2025, and have further improved our long-term outlook, with sales of more than £40 billion now expected by 2031.
Core operating profit rose 11% without currency fluctuations, although the total fell 40% to £4 billion when including a one-off charge of £1.8 billion relating to the settlement of Zantac litigation.
GSK sees 2025 turnover growth at constant exchange rates of between 3% to 5%, with core operating profit growth of between 6% to 8%.
